Last updated: February 14, 2026
Overview
NDC 43547-0599 corresponds to Tucatinib (trade name: Tukysa), a targeted therapy approved by the FDA in April 2020. It treats HER2-positive breast cancer, including metastatic cases. Its market position is influenced by competitive landscape, clinical efficacy, regulatory status, and manufacturing dynamics.
Market Landscape
- Indication: HER2-positive breast cancer, especially heavily pretreated metastatic disease.
- Approved Use: In combination with trastuzumab and capecitabine.
- Market Penetration: Early adoption phase, with growth driven by expanding indications and combination therapies.
Competitive Environment
- Major Competitors: Trastuzumab deruxtecan (Enhertu), Pertuzumab (Perjeta), T-DM1 (Kadcyla).
- Market Share: Tucatinib holds an estimated 10-15% share within the HER2-positive metastatic breast cancer segment as of 2022, with rapid growth anticipated.
- Pricing Compared to Peers:
- Tucatinib: Packaged as 300 mg tablets, with wholesale acquisition cost (WAC) approximately $6,800 per month.
- Enhertu: $11,800 per infusion.
- Kadcyla: $8,100 per vial.
Pricing Dynamics
- The initial pricing of tucatinib aligns with the high-cost targeted therapy segment but remains more affordable than some monoclonal antibody-drug conjugates like Enhertu.
- Discounting models project a reduction of 10-15% in the retail price over five years, driven by biosimilar competition and generic entry for combination drugs.
Market Growth Projections
| Year |
Estimated Market Value (USD billions) |
Compound Annual Growth Rate (CAGR) |
Notes |
| 2022 |
$300 million |
— |
Initial uptake phase |
| 2025 |
$800 million |
30% |
Expansion to second-line therapy, new indications |
| 2030 |
$1.5 billion |
15-20% |
Broader adoption, potential label expansion |
Pricing Projections (2023-2030)
- 2023: $6,800/month, stabilizing as uptake increases.
- 2025: Averaging $6,300/month due to discounts and increased competition.
- 2030: Expected to decline to approximately $5,500-$6,000/month in response to biosimilar market entries.
Regulatory and Reimbursement Factors
- FDA: Approval based on phase 2 data; ongoing phase 3 trials may expand indications.
- Pricing & Reimbursement: CMS and private payers adopting value-based models for oncology drugs. Reimbursement levels will influence net pricing.
- Potential for Price Erosion: As biosimilars and generics enter, competition will reduce prices.
Key Risks & Opportunities
- Risks:
- Delays in Phase 3 trials or negative interim results.
- Market saturation by competing therapies.
- Reimbursement restrictions due to cost containment policies.
- Opportunities:
- Label expansion to earlier lines.
- Combination with novel agents.
- Geographic expansion, particularly in Europe and Asia.
Summary
Tucatinib (NDC 43547-0599) is positioned within a high-growth segment of metastatic HER2-positive breast cancer. Its pricing starts high but faces downward pressure from competition and biosimilarity. Market revenues are projected to reach approximately $1.5 billion worldwide by 2030, with average monthly prices declining by roughly 10-15% over that period.
Key Takeaways
- Tucatinib’s initial monthly wholesale price is approximately $6,800.
- Market value is projected to grow at a CAGR of around 20% from 2022 to 2025.
- Price erosion is anticipated due to biosimilar and generics entry, reducing prices to about $5,500-$6,000 by 2030.
- The drug’s competitive advantage stems from unique efficacy in brain metastases management.
- Regulatory developments and clinical trial outcomes remain critical to future market expansion.
FAQs
- How does tucatinib compare to other HER2-targeted therapies in terms of price?
- What factors could accelerate the market penetration of tucatinib?
- How are reimbursement policies impacting tucatinib’s pricing outlook?
- When can biosimilars or generics be expected to impact tucatinib’s pricing?
- What geographic regions are expected to see the fastest uptake of tucatinib?
Sources
- U.S. Food and Drug Administration. Tucatinib approval memo. (2020).
- IQVIA, Drug Trend Report 2022.
- CMS and private payor reimbursement guidelines.
- Company press releases and pipeline updates.
- Market research firms’ oncology drug forecasts (e.g., Evaluate Pharma, GlobalData).
